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Immune competence is of importance for the
occurrence and outcome of malignancies, as
exemplified by the effects of immune check-
point inhibitors in the treatment of
malignancies.1 An increased risk for malig-
nancies has been one of the main concerns
since the introduction of biological disease-
modifying anti-rheumatic drugs (bDMARDs)
for the treatment of chronic inflammatory
arthritis. Most treatment guidelines have
therefore issued caution against using
bDMARDs (tumour necrosis factor inhibitors
(TNFi) in particular) in patients with a history
of cancer within 5–10 years. So far, most
(though not all) studies of cancer incidence
following treatment with TNFi and other
bDMARDs, and of recurrence of pre-
treatment cancers following treatment with
TNFi, have been reassuring.2–9 The 2015
ACR recommendations for treatment of rheu-
matoid arthritis (RA) recommend that
patients with a history of previous solid organ
malignancy should be treated as patients with-
out this condition,10 though acknowledging
the low level of evidence, whereas previous
recommendations suggested rituximab.11
Similarly, there is no consensus regarding
the time period from cancer diagnosis until
the safe initiation of a bDMARD. Thus, scien-
tific evidence supporting clinical decision-
making in this context is scarce.
The aim of the present study was to assess
the relative use of different bDMARDs in
patients with RA and history of cancer. We
used real-life data from the DANBIO (Den-
mark), ROB-FIN (Finland), NOR-DMARD
(Norway) and ARTIS (Sweden) bDMARD reg-
isters. We identified patients with RA who
initiated any bDMARD between year
2010–2017, regardless of type or number of
prior bDMARDs. We identified patients with
a clinical rheumatologist-assigned diagnosis
of RA regardless of fulfilment of exact classifi-
cation criteria. We identified the subgroup of
patients with prior malignancy 10-year prior
to starting the bDMARD in question through
linkage to national cancer registers. Any
malignancy (invasive or in situ) apart from
benign tumours was defined as malignancy.
Patients could contribute more than one
treatment course. Both non-melanoma and
melanoma skin cancer were included. The
frequency of RA patients with a history of
malignancy (according to the definition
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Key messages
What is already known about this subject?
► According to RA treatment recommendations,
patients with a history of previous solid organ
malignancy should be treated as patients without
this condition, although the level of evidence is low.
What does this study add?
► This large multinational register-based study
quantified the proportion of RA patients starting
a bDMARD who had a prior malignancy (1–6%).
This proportion was significantly higher for
rituximab (8–17%), demonstrating a preference for
rituximab in this patient population.
How might this impact on clinical practice?
► There is a reluctancy to use bDMARDs and especially
TNF inhibitors in RA patients with a history of
malignancy, which might imply a risk for
undertreatment of some patients. This underscores
the need for more data.
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above) in each bDMARD group, as well as basic demo-
graphic and disease characteristics (age, gender, number
of prior bDMARDs, years from cancer diagnosis until start
of the bDMARD) was assessed across the different
bDMARD groups. Switches from bio-original to biosimi-
lar were regarded as one treatment.
A total of 42 638 RA patients initiating a bDMARD
treatment were included (table 1). Initiators of non-
TNFi biologics were generally older than TNFi-
initiators, with the highest age at start for rituximab,
especially in Sweden and Finland (table 1). Overall,
among the bDMARD initiators in Denmark, Finland,
Norway and Sweden, 344/11 230=3%, 288/4766=6%,
56/1876=3% and 1703/24 766=6.9%, respectively, had
prior cancer. Whereas there was little variation across
individual TNFi inhibitors ranging from 1% to 6%, the
proportion of patients with a history of cancer at treat-
ment start was higher among patients on non-anti-TNF
bDMARDs, especially for rituximab (8–17%). The med-
ian time (years) since the cancer diagnosis ranged from 2
to 7 years, with a tendency towards a shorter time for
rituximab (table 1).
As expected, we noted that the proportion of patients
starting a bDMARD during the period 2010–2017 with
a prior malignancy was low. Among these initiators, how-
ever, there was a clear preference for non-TNFi, in parti-
cular rituximab. The latter could in part be explained by
differences in age at treatment start, as patients on ritux-
imab tend to be older compared with patients on other
bDMARDs. However, the small differences in median age
among patients with history of cancer across the
bDMARD groups under study supports the hypothesis
that there is a preference for rituximab by clinicians for
treatment of patients with history of cancer. Rituximab is
being used for several haematological malignancies,
which might at least partly explain the preference,
although the underlying evidence for this preference in
other types of cancers remains incomplete. Another
interesting observation was that the proportion of female
patients with a history of cancer was somewhat higher
compared with patients with no history of cancer in the
TNFi groups, but not in the non-TNFi group. A possible
explanation for this could be the different choice of
bDMARD in different types of cancer. Finally, there is
heterogeneity not only in treatment channelling, but
also due to different prescription patterns across
countries.
Our results underscore both the reluctance to use
bDMARDs and especially TNFi in RA patients with
a history of malignancy, which implies a risk for under-
treatment of some patients, and the need for more data
on the benefit–risk ratio in this treatment context.
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